Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Its top TV program by spend was the Oscars broadcast, another of the month’s major cultural events. Taking sixth place was Novo’s Ozempic, up from No. 10 the previous month, thanks to $21.7 ...

Front and center of this is Novo Nordisk (NYSE: NVO), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

A consumer watchdog group is challenging Sinclair's latest TV station sale, citing concerns about the broadcaster's past regulatory issues. A consumer watchdog organization has challenged Sinclair ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic. The stock dropped as much as ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...